| |
ORIGINAL RESEARCH
The effect of a metaphylactic pulse dosing in-feed antimicrobial
strategy on finishing pig health and performance
Don Walter, DVM; J. Tyler Holck DVM, MS, MBA; Steve Sornsen,
DVM, MS; Chad Hagen, PhD; Isabel Turney Harris, DVM, PhD
Walter D, Holck JT, Sornsen S et al. The effect of a metaphylactic
pulse dosing in-feed antimicrobial strategy on finishing pig
health and performance. Swine Health Prod. 2000;8(2):65-71.
This article is also available in PDF
format.
DW: Boehringer Ingelheim Vetmedica Inc., 1051 Barrington Road,
Iowa City, Iowa 52245; JTH: Novartis Animal Health US, Inc. SS:
Seaboard Farms; CH, Iowa Select Farms; ITH: Iowa State University
Summary
Purpose: To compare the effect of metaphylactic pulse
dosing with either a continuous-feed antimicrobial medication
strategy or no feed medication on finishing pig health and performance.
Methods: Barrows (n = 1092) from a herd naturally infected
with endemic respiratory pathogens were assigned by pen to one
of three treatment groups: a "Continuous" group that
received alternating doses of tiamulin plus chlortetracycline
on weeks 2,4,7,10, and 13 interspersed with a reduced concentration
of chlortetracycline alone during weeks 3,5,6,8,9,11, and 12;
a "Pulse" group, which received in-feed pulse dosing
with tiamulin plus chlortetracycline only in weeks 2,4,7,10, and
13 with no medication during the other study weeks; or nonmedicated
Controls that received nonmedicated feed throughout the trial.
Growth performance, survivability, and seroconversion to various
pathogens were measured.
Results: Both metaphylactic Pulse and Continuous medication
strategies improved growth rate, feed intake, feed conversion
efficiency, and survivability in the presence of naturally occurring
mycoplasmal and viral (swine influenza virus, porcine reproductive
and respiratory syndrome virus) respiratory disease compared to
Controls. Pulse but not Continuous medication permitted sufficient
natural exposure to Mycoplasma hyopneumoniae to stimulate
active humoral immunity.
Implications: Both feed medication strategies significantly
improved performance versus nonmedicated controls. Metaphylactic
pulse dosing with appropriate antimicrobials may improve growth
performance while permitting exposure to and stimulation of active
immunity against endemic mycoplasmal pneumonia.
Keywords: swine,
pulse dosing, metaphylaxis, antibiotic, feed medication, tiamulin,
chlortetracycline, serology, Mycoplasma hyopneumoniae.
Received: May 12, 1999
Accepted: December 15, 1999
The effectiveness of
tiamulin or the tetracycline derivatives in controlling porcine
bacterial and mycoplasmal pneumonia is markedly enhanced when
the two antibiotics are given concurrently.1-6 Nontraditional
medication strategies, such as pulse dosing with this combination
of antibiotics, have been shown to be effective for controlling
a variety of pig diseases.6-9 Pulse dosing is the practice
of providing a limited number of short-term medication "pulses"
at therapeutic doses, separated by nonmedicated intervals. Pulse
doses may vary in number and duration depending upon the circumstances.
Pulse dosing is predicated upon the hypothesis that intermittent
therapeutic antimicrobial medication allows natural exposure to
endemic pathogens, but will abbreviate the infection incubation
process before a costly clinical disease outbreak can occur. Allowing
natural exposure to stimulate acquired active immunity provides
animals with long-term protection (e.g., to slaughter or entry
into the breeding herd) once the short-term protection of medication
is discontinued. While the rationale behind pulse dosing is intuitively
logical, we are unaware of any data supporting this specific hypothesized
immune mechanism.
The present study was conducted to determine
- whether in-feed pulse dosing was as effective in controlling
the clinical and growth-limiting effects of respiratory disease
as continuous in-feed medication; and
- whether pulse dosing allowed pigs to mount an immune response
to natural exposure to respiratory pathogens.
Materials and methods
This 16-week study was conducted in a commercial, single-source,
age-segregated sow farm/nursery/finisher (three-site system) in
the Midwest. The rate and efficiency of weight gain in this herd
was typically depressed approximately 8-12 weeks after pigs were
placed into finishing. Feed consumption, however, remained close
to normal during this period. Diagnostic evidence of infectious
respiratory disease due to viral, mycoplasmal, and bacterial pathogens
was common but inconsistent.
Treatments
One thousand one hundred and four (1104) 11-week-old barrows
from a single source were placed in the building over a 2-day
period in August 1997. On the first day after placement, all pigs
were individually weighed and identified with an eartag. One thousand
ninety-two (1092) pigs were selected for the study (one dead pig
and 11 pigs with extreme high or low weights were excluded from
allotment).
Selected pigs were blocked by weight and randomly allotted
to pens within blocks on the day after the initial weighing. Pens
within blocks were randomly assigned to one of the following treatments:
- "Continuous" group, which received tiamulin
hydrogen fumarate (Denagard(TM) 10 Medicated Premix,
Boehringer Ingelheim Vetmedica Inc.; St. Joseph, Missouri) at
35 g per ton during weeks 2, 4, 7, 10, and 13 of the study (Table 1). During these weeks, barrows
also received continuous in-feed chlortetracycline hydrochloride
(HCl)(AUREOMYCIN(R) 90 Granular Premix, Roche Vitamins
Inc.; Parsippany, New Jersey) at a dose of 22 mg per kg (10 mg
per lb) bodyweight (BW) daily. During weeks 3, 5, 6, 8, 9, 11,
and 12, chlortetracycline HCl was added to the feed daily at
a rate of 100 g per ton. Nonmedicated feed was offered during
weeks 1 and 14-16.
- "Pulse" group, which received concurrent
feed medication of tiamulin hydrogen fumarate at 35 g per ton
plus chlortetracycline HCl at a dose of 22 mg per kg (10 mg per
lb) BW daily during weeks 2, 4, 7, 10, and 13 as a 'pulse' medication
(Table 1). Nonmedicated feed was
provided during the remaining weeks (1, 3, 5, 6, 8, 9, 11, 12,
and 14-16); or
- nonmedicated "Control" group, which received nonmedicated
feed throughout the study.
Housing
The research barn was a tunnel-ventilated finishing facility
with natural ventilation capability. It contained 44 pens, each
measuring 3 x 6 m (10 x 19 feet) and equipped with one five-hole
dry feeder and two nipple waterers. The floor was totally slatted
concrete with under-slat scrapers for manure removal. The barn
was managed in an all-in-all-out (AIAO) manner and was one of
10 barns on a continuous-flow finishing site.
Two replicate pens of pigs for each of three treatment groups
were represented within each of seven blocks. A total of 42 pens
were included in the study, with 26 pigs per pen for an initial
stocking density of approximately 0.69 m2 (7.3 sq.
ft) per pig.
Growth
Pigs were individually weighed at allotment and at the end
of the study (16 weeks post-allotment). Pen weights were collected
by moving the entire pen of pigs onto a pen scale located at the
end of the barn on a biweekly basis.
Feed
Feed was offered ad libitum to all pigs in all pens. Feed was
delivered to each pen feeder using a Mosdal feed cart and the
weight of feed delivered to each feeder was recorded. Identical
diets were offered to all three treatment groups at all times
during the study with the exception of the added medication (Table 1). Diet formulations were adjusted
on a biweekly basis, and remaining feed was removed, weighed,
and subtracted from the amount of feed delivered to determine
net feed disappearance.
Health
Two pigs from each pen were randomly selected and serially
bled biweekly beginning on allotment day. The sera were stored
until testing at -70 degrees C. Samples were tested using
- porcine respiratory and reproductive syndrome enzyme-linked
immunosorbent assay (Herd Check(TM) PRRSV Antibody Test Kit,
IDEXX Corp.; Westbrook, Maine),
- Mycoplasma hyopneumoniae Tween 20 ELISA (performed
by Boehringer Ingelheim Vetmedica),
- swine influenza hemagglutination-inhibition assay (SIV
HI) (performed by Iowa State University Veterinary Diagnostic
Laboratory),
- Salmonella mix-ELISA (Danish mix-ELISA procedure performed
by Boehringer Ingelheim Vetmedica),
- Lawsonia intracellularis indirect-fluorescent antibody
(IFA) assay (performed by Boehringer Ingelheim Vetmedica); and
- transmissible gastroenteritis virus hemagglutination-inhibition
assay (TGEV HI) (performed by Iowa State University Veterinary
Diagnostic Laboratory).
Pigs were not vaccinated for any of the monitored diseases.
In conformity with standard site procedure, affected pigs were
injected with tylosin during weeks 1-6 of the study; all injections
of tylosin were discontinued by week 6 of the study. During weeks
7-14, individual pigs affected with respiratory diseases were
injected with penicillin derivatives.
Statistical analysis
Performance data were analyzed using repeated-measures ANOVA
techniques using the pen as the experimental unit for all production
data. c2 analysis was used to assess mortality data.
Serologic data were evaluated using statistical process control
methods10,11 to estimate the timing of serologic changes.
Economic analysis
Potential economic benefits of antibiotic inclusion in the
feed were analyzed with a partial budget.12-15 Partial
budget analysis provides a powerful tool to assess the cost effectiveness
of therapeutic interventions.16 It requires that only
those factors affected by the treatment be included in the analysis,
such that:
Net benefit or loss of an intervention =
associated changes in revenues -
associated changes in cost
Because in this study we determined that final bodyweight,
feed intake, and mortality differed significantly between the
Control and the two treatment groups, but not between the Pulse
and Continuous groups, we compared the average of the two treatment
groups to the nonmedicated control, but did not compare between
different antibiotic regimes. Accordingly, final bodyweight, feed
intake, and mortality were included in an economic model consistent
with the study design, which assumed constant growth over a 16-week
period, such that:
Net benefit or loss per group =
(increase in lb of hogs marketed x
market price of hogs) -
(increase in lb of feed consumed x cost of feed) -
treatment cost
Dividing this sum by the initial number of animals in the group
yields the quantity net benefit or loss per head. Although the
treatment costs in the Continuous group were higher than those
in the Pulse group because the Continuous group received 7 additional
weeks of chlortetracycline at 100 g per ton, we used an average
treatment cost for both groups of $2.30 per head for the economic
analysis.
The outcome of partial budget analysis depends greatly on both
the local cost structure of the operation under study and the
prevailing market conditions.13 However, sensitivity
analysis15,17 provides a means to systematically vary
uncertain factors in the analysis. Therefore we created a matrix
wherein both feed cost and market hog price were varied, and the
net benefit or loss associated with antibiotic inclusion treatment
was assessed over a wide range of financial scenarios.
Results
Allotment and final body weights
Body weights did not differ among treatment groups at allotment
(63 lb; 28.6 kg). Pigs in the Control group (P <.0001)
had significantly lower final weights (i.e., at week 16) than
those in the Continuous and Pulse groups (Figure
1), but bodyweights did not differ significantly between the
Continuous and Pulse groups. Final weight (Continuous = 116.3
kg [255.9 lb], Pulse = 116.0 kg [255.2 lb]) differences were significant
(P <.0001) between each of the seven blocks at the beginning
and end of the study. No interaction was detected between treatment
and block.
Growth rate
Average daily gain (ADG) was significantly (P =.02)
greater in both medicated groups (Continuous = 754 g [1.66 lb]
per day, Pulse = 732 kg [1.61 lb] per day) compared to the Control
group (695 g [1.53 lb] per day) during the first 2 weeks on trial,
even though treated pigs received medicated feed only during week
2. Average daily gain was greater for both medicated groups compared
to controls for the overall study period (P <.0001;
Figure 1).
Feed intake and feed efficiency
Both medicated groups had significantly improved overall feed
intake (P =.004) and feed conversion efficiency (P
=.02) compared to Controls. There were no significant differences
in feed intake or feed conversion efficiency between the Pulse
and Continuous groups (Figure 1).
Mortality
Both medicated groups had significantly lower mortality rates
than the Control group (P <.001; Figure
2). There was no significant difference in mortality rate
between the Pulse and Continuous groups.
Serologic response
Pigs were seronegative to PRRSV at the initiation of the study,
with a sampling frequency (42) adequate to detect a 10% prevalence
rate with a 99% degree of confidence. Seroconversion to PRRSV
was evident after 2 weeks, with 43% of the animals testing positive
(based upon an S:P ratio breakpoint of 0.4) on the ELISA test.
All tested animals had seroconverted to PRRSV by week 4. PRRSV
ELISA titers peaked 6 weeks into the study (Figure
3). There were no differences in seroconversion to PRRSV detected
among treatments.
Low and declining titers to SIV were present at the beginning
of the study in all treatment groups. A significant rise in SIV
titers occurred at 12 weeks in all three treatment groups (Figure 4). No differences in seroconversion
to SIV were detected among the study groups.
Fourteen percent of the pigs tested were seropositive (S:P
ratio breakpoint of 0.25) to M. hyopneumoniae at the initiation
of the study, with positive animals present in each of the treatment
groups. A significant rise in M. hyopneumoniae titers occurred
beginning at 12 weeks in both the Pulse and the Control groups,
and at 16 weeks for the Continuous group (Figure
5 and Figure 6).
Pigs were seropositive to TGEV at the initiation of the study
with significant increases in titers at 4 weeks in all three treatment
groups. TGEV seroconversion coincided with an observed increase
in diarrhea throughout the barn. No differences in TGEV titers
were detected among treatments.
There was minimal seroconversion to Lawsonia intracellularis
and Salmonella at weeks 0 and 16, with no significant differences
between groups.
Cost:benefit analysis
Assuming a fixed growth period, the economic advantage to using
in-feed medications (due to additional pork produced [greater
weight gain and reduced mortality]) more than offset the cost
of medication under most of the feed cost and market hog price
scenarios we modeled for this herd (Table
2). As an example, the use of feed medication was projected
to be profitable when finishing feed costs were $0.06 per lb and
market hog prices were >$22 per cwt. The sensitivity analysis
constructed from this trial resulted in a net benefit of $1-$5
per head with live animal market prices of $30-$50 per cwt for
this herd.
Discussion
Because antibiotics do not affect viruses, the similar serologic
response to the three viruses tested--PRRSV, SIV, and TGEV--in
all three treatment groups was not unexpected. The serologic profile
we observed for PRRSV was similar to those generated in controlled
exposure studies with naïve animals,18 although
we observed a slower decline in titers at 12-16 weeks. The PRRSV
serology suggests that pigs were exposed to PRRSV soon after being
placed in the study facility, with additional exposure occurring
10-14 weeks post-placement. The serologic profile for SIV is consistent
with waning maternal immunity at placement and exposure 8-12 weeks
post placement. The progression of exposure to the viruses tested
was: TGEV prior to arrival, PRRSV at 0-2 weeks, and SIV at 8-12
weeks post placement, with no differences in exposure detected
among treatment groups.
Although we did not perform slaughter checks or necropsy symptomatic
pigs to confirm the presence of mycoplasma-associated respiratory
disease, seroconversion to M. hyopneumoniae has been shown
to be associated with the development of gross lesions of mycoplasmal
pneumonia and clinical signs typical of the disease.19-21
Results suggest that adequate exposure to M. hyopneumoniae
for detectable changes in serologic response occurred between
weeks 8-12 for the Pulse and Control groups, but was delayed in
the Continuous group until weeks 14-16, when continuous medication
had been withdrawn. This difference in serologic response suggests
that the pigs in the Control and Pulse groups received adequate
natural exposure to M. hyopneumoniae during the nonmedicated
period(s) to generate an active immune response. The Continuous
group, although housed in the same airspace with the other groups
and continuously exposed to M. hyopneumoniae, apparently
received inadequate M. hyopneumoniae exposure to stimulate
an immune response until the continuous medication was withdrawn
late in the study (weeks 14-16). It is unlikely that the penicillin
derivatives with which we injected affected pigs during the period
of seroconversion to M. hyopneumoniae functioned as a confounder
in this study, since penicillin is ineffective against M. hyopneumoniae.22
Seroconversion to M. hyopneumoniae using a monoclonal
blocking ELISA assay has been shown to occur as early as 8 days
post-infection in an experimental M. hyopneumoniae aerosol
challenge study.20 Seroconversion was detected as early
as 9 days post-intratracheal challenge using a Tween-20 ELISA
assay.23 When exposed to these intratracheally challenged
pigs, in-contact controls seroconverted using the Tween 20 ELISA
assay as early as 7 days post-exposure.23 ELISA seroconversion
to M. hyopneumoniae is a reliable indicator of the presence
of antibody, which may be due to passive maternal transfer, vaccination,
or natural exposure. In the present study seroconversion to M.
hyopneumoniae occurred in mid-to-late finishing in unvaccinated
pigs. This is well past the age when maternal immunity would have
declined to an undetectable degree, indicating seroconversion
was due to natural exposure. Protective immunity develops in swine
recovering from mycoplasmal pneumonia.22 Therefore,
seroconversion due to natural exposure in the Control and Pulse-medicated
pigs in the present study suggests that protective, active immunity
developed in those groups.
Continuous medication improved growth performance but may have
prevented stimulation of active immunity against mycoplasmal pneumonia,
leaving animals immunologically naïve and potentially susceptible
to subsequent re-exposure to M. hyopneumoniae when medication
was withdrawn. Continuous feed antibiotic medication has also
been shown to decrease the prevalence of seroconversion to Lawsonia
intracellularis in experimentally infected pigs.24
The lack of a difference in growth performance we observed between
the Pulse and Continuous groups suggests that pulse dosing is
adequate to protect growth performance while permitting an active
immune response, which may potentially provide long-term protection
against endemic disease.
The nomenclature of human medicine with regard to "pulse,"
"intermittent," or "discontinuous" dosing
differs somewhat from that of veterinary medicine. In human medicine,
these terms refer primarily to once-daily dosing with antibiotics
rather than the multiple daily doses that are typically prescribed.25,26
In swine veterinary practice, the duration of medication pulses
as well as the duration of the nonmedicated intervals are usually
on the order of days or weeks.6-8
Mechanisms that contribute to the reported success of pulse
dosing in human medical practice include the post-antibiotic effect
(PAE),26,27 post-antibiotic sub-minimum inhibitory
concentration (MIC) effect (PA SME),27 delayed tissue
antibiotic depletion kinetics,28 post-antibiotic leukocyte
enhancement (PALE),29,30 and adhesion inhibition.31
Some of these effects are relatively short-lived32
and it is not known whether they would contribute significantly
to the outcome of veterinary pulse dosing as described herein.
However the interaction between sub-MICs of antibiotics and the
immune system (especially phagocytosis) is probably of great importance27
and the contribution of a functional immune system to the role
of antibiotics in resolving infectious disease is recognized.33,34
Our observation that seroconversion to M. hyopneumoniae
was inhibited in pigs dosed with the low inclusion rate of 100
g per ton CTC (after pulse dosing with therapeutic levels of tiamulin
and CTC) was somewhat surprising in light of the low dose administered,
and may possibly be due to a PA SME or related mechanism. The
PA SME differs fundamentally from the PAE and SME phenomena, even
though its name implies similarity. Briefly, the PAE refers to
the continued suppression of bacterial growth after administration
of the drug is discontinued, an effect that generally persists
for <2-4 hours.27 The SME refers to decreased expression
of virulence factors (e.g., adhesins, toxins, normal morphology,
etc.), not necessarily decreased bacterial growth, when an organism
is exposed to sub-MIC levels of drug.35 SMEs of tiamulin
against Pasteurella multocida and Actinobacillus pleuropneumoniae
virulence factor expression including reduced production of capsular
polysaccharides, iron-regulated proteins, and hemolysins have
been demonstrated.36 The PA SME refers to a prolonged
period of growth suppression (and concomitant virulence factor
expression) when bacteria are exposed to sub-inhibitory concentrations
of drug after supra-inhibitory concentrations.27
Prolonged growth suppression of M. hyopneumoniae might
explain the lack of seroconversion in the presence of natural
exposure in the continuously medicated group of pigs in the present
study, although a PA SME specifically for chlortetracycline against
M. hyopneumoniae has not been reported.
The strategic use of pulse dosing is an example of 'metaphylactic'
use of antimicrobials. Metaphylaxis can be defined as 'early treatment'
after natural exposure to endemic disease organisms. With metaphylactic
applications, some pathogen exposure generally occurs but intervention
is initiated prior to an actual disease outbreak. The present
study provides evidence that pulse dosing in this metaphylactic
manner may facilitate the added benefit of stimulating active
immunity (via natural exposure to endemic pathogens) for long-term
immunologic protection once the short-term 'cover' of medication
is discontinued. Pulse dosing also decreased the total duration
of antibiotic use from 12 weeks to 5 weeks in this herd, a potentially
important additional consideration in light of current concerns
regarding potential overuse of antimicrobials in food animal production.
Metaphylaxis, implemented properly, may actually provide better
health and performance with reduced antimicrobial use than traditional
prophylactic or therapeutic approaches.
It is unlikely that there will be any 'cook book' metaphylactic
program suitable for every herd. Diagnostics are needed to identify
the organisms involved, their antimicrobial susceptibility profile,
when they infect pigs, and when clinical disease typically occurs
in that production system. Knowledge of the spectrum of activity
and tissue distribution of the available antimicrobial options
is needed to design a rational antimicrobial intervention plan
whether it is prophylactic, metaphylactic, or therapeutic in intent.
Swine practitioners are well equipped to provide that service,
information, and advice to their pork producing clients.
Strategic pulse dosing may be appropriate for conditions where:
- management techniques (such as early weaning and age-segregated
rearing) are unable to exclude infection of all piglets resulting
in disease outbreaks in later stages of production;
- vaccines may not exist or may not be perceived to be cost-effective
for the production-limiting diseases present;
- vaccination prior to disease exposure does not occur;
- multiple disease challenges exist, requiring the use of a
broad-spectrum intervention tool; or
- continuous use of dietary antimicrobials is unacceptable.
Implications
- Both Pulse and Continuous feed medication strategies significantly
improved performance versus nonmedicated Controls as measured
by growth rate, feed intake, feed conversion efficiency, and
survivability.
- Metaphylactic pulse dosing with appropriate antimicrobials
may improve growth performance while permitting exposure to and
stimulation of active immunity against mycoplasmal pneumonia.
- Continuous medication may improve growth performance without
permitting sufficient natural exposure to and stimulation of
active immunity against mycoplasmal pneumonia, leaving animals
immunologically naïve and potentially susceptible to subsequent
re-exposure when medication is withdrawn.
Acknowledgements
The authors thank Jeff Beekhuizen, Kevin Karhoff, Court Garloff,
Dale Polson, Dave Baum, and the Health Management Center team
of Boehringer Ingelheim Vetmedica Inc. for their valuable assistance
in the conduct and analysis of this study.
References - refereed
1. Burch D, Jones G, Heard T, Tuck R. The synergistic activity
of tiamulin and chlortetracycline: In-feed treatment of bacterially
complicated enzootic pneumonia in fattening pigs. Vet Rec.
1986;119:108-112.
8. Kavanagh N. The effect of pulse medication with a combination
of tiamulin and oxytetracycline on the performance of fattening
pigs in a herd infected with enzootic pneumonia. Irish Vet
J. 1994;47:58-61.
9. Jouglar J, Borne P, Sionneau G, Bardon T, Echlache D. Evaluation
of the efficacy of the tiamulin-oxytetracycline combination premix
in the prevention of enzootic pneumonia in slaughter pigs. Rev
Med Vet. 1993;144(12):981-988.
10. Shewhart W. In: Statistical method from the viewpoint
of quality control. Dover publications, Mineola New York,
1939 (reprinted 1986).
11. Wheeler D, Chambers D. In: Understanding Statistical
Process Control. SPC press, Knoxville Tennessee, 1992.
12. Hoblet KH, Miller GY, Bartter NG. Economic assessment of
a pseudorabies epizootic, breeding herd removal/repopulation,
and downtime in a commercial swine herd. JAVMA. 1987;190(4):405-409.
13. Parsons TD, Pitcher PM, Johnstone C. Economic analysis
of an epizootic of pseudorabies and subsequent production following
the institution of a vaccination program in a Pennsylvania swine
herd. JAVMA. 1990; 197(2):188-191.
14. Lane DM, Rendleman
CM, Ott SL. Using partial budgets to analyze selected management
practices associated with reduced preweaning mortality. Swine
Health Prod. 1997;5(3):95-102.
15. Drum SD, Marsh WE.
How to use partial budgets to predict the impact of implementing
segregated early weaning in a swine herd. Swine Health Prod.
1999;7(1):13-18.
16. Boehlje MD, Eidman VR. Farm Management. New York,
New York: Wiley and Sons. 1984.
17. Parsons TD, Smith G, Galligan DT. Economics of porcine
parvovirus vaccination assessed by decision analysis. J Prev
Vet Med. 1986;4:199.
20. Sorensen V, Ahrens P, Barford K, Feenstra A, Feld N, Friis
N, Bille-Hansen V, Jensen N, Pedersen M. Mycoplasma hyopneumoniae
infection in pigs: Duration of the disease and evaluation of four
diagnostic assays. Vet Micro. 1997;54:23-34.
21. Sitjar M, Noyes
E, Simon X, Pijoan C. Relationships among seroconversion to Mycoplasma
hyopneumoniae, lung lesions, and production parameters in
pigs. Swine Health Prod. 1996;(4)6:273-277.
22. Ross R. Mycoplasmal diseases. In: Diseases of Swine,
7th ed, 1992;537-543.
23. Sheldrake R, Gardner I, Saunders M, Romalis L. Serum antibody
response to Mycoplasma hyopneumoniae measured by enzyme-linked
immunosorbent assay after experimental and natural infection of
pigs. Aus Vet J. 1990;67(2):39-42.
24. Schwartz K, Knittel
J, Walter D, Roof M, Anderson M. Effect of oral tiamulin on the
development of porcine proliferative enteropathy in a pure-culture
challenge model. Swine Health Prod. 1999;7(1):5-11.
25. Donaldson J, Martin G, Maltby C, Seyward E. The efficacy
of pulse-dosed antibiotic therapy in the management of persistent
otitis media with effusion. J Otolaryng. 1990;19(3):175-178.
26. Kirby W, Craig W. Theory and applications of pulse dosing:
A summary of the symposium. Rev Inf Dis. 1981;3(1):1-3.
27. Cars O, Odenholt-Tornqvist I. The post-antibiotic sub-MIC
effect in vitro and in vivo. J Antimicrob Chemother. 1993;(31)
suppl D, 159-166.
28. Bergan T. Pharmacokinetics of tissue penetration of antibiotics.
Rev Infect Dis. 1981;3:45-66.
29. MacDonald P, Wetherall B, Pruul H. Postantibiotic leukocyte
enhancement: Increased susceptibility of bacteria pretreated with
antibiotics to activity of leukocytes. Rev Inf Dis. 1981;3:38-44.
30. Raponi G, Keller N, Overbeek B, Rosenberg-Arsak M, van
Kessel K, Verhoef J. Enhanced phagocytosis of encapsulated Escherichia
coli strains after exposure to sub-MICs of antibiotics is
correlated to changes of the bacterial cell surface. Antimicrob
Agents Chemother. 1990;34:332-336.
31. Ofek I, Beachey E, Eisenstein B, et al. Suppression of
bacterial adherence by subminimal inhibitory concentrations of
beta-lactam and aminoglycoside antibiotics. Rev Infect Dis.
1981;1:832-837.
32. LeBel M, Spino M. Pulse dosing versus continuous infusion
of antibiotics: pharmacokinetic-pharmacodynamic considerations.
Clin Pharm. 1988;14:71-95.
33. Bakker-Woudenberg I, Roosendaal R. Impact of dosage regimens
on the efficacy of antibiotics in the immunocompromised host.
J Antimicrob Chemother. 1988;21:145-147.
34. Roosendaal R, Bakker-Woudenberg I, van den Berge-van Raffe
M, Michel M. Continuous versus intermittent administration of
ceftazidime in experimental Klebsiella pneumoniae pneumonia
in normal and leukopenic rats. Antimicrob Agents Chemother.
1986;30:403-408.
35. Lorian V, Gemmel C. Effects of low antibiotic concentrations
on bacteria. Effects on ultrastructure, virulence and susceptibility
to immunodefenses. In: Antibiotics of Laboratory Medicine,
3rd ed. 1991;493-555.
References - nonrefereed
2. Blagovic S, Bilic V. The synergistic activity of tiamulin
and oxytetracycline(Geoltilin(R)): Investigation of
the sensitivity of bacteria and the possibility of preventing
colibacillosis, dysentery, and pneumonia in pigs. Proc IPVS.
1986:144.
3. Heard T. The control of some pneumonia problems in pigs
by strategic medication procedures. Proc IPVS. 1986:284.
4. Morgan J, Aitken I, Collins P, Shearn M, Dalziel R, Burch
D, Ripley P. The efficacy of in-feed antibiotics for the prevention
of experimentally-induced Actinobacillus pleuropneumonia.
Proc Euro Assoc Vet Pharm Tox. 1994:204.
5. Puig J. Effects on pig performances (ADG, FCR) after oral
treatment with tiamutin-oxytetracycline combination in an enzootic
pneumonia naturally infected herd. Proc IPVS. 1994:286.
6. Walter D. An evaluation of the performance of tiamulin plus
chlortetracycline pulse-dosed in medicated feed versus chlortetracycline
alone and tiamulin alone in commingled feeder pigs with naturally
occurring disease. Proc AASP Ann Meet. 1995:101-104.
7. Scattolini E, Montanari L, Bresciani C. Field evaluation
of performance improvement in fattening pigs after strategic in
feed "pulse medication" based on tiamulin and chortetracycline.
Proc IPVS. 1994:324.
18. Polson D, Johnston D, Karhoff K, Catlett K. Using statistical
process measurement methods in conjunction with post-vaccination
antibody response curves to continuously measure natural PRRS
virus exposure and compliance to PRRS vaccination in a pig production
system. PRRS Aujeszky's Dis Proc. 1999:277-278.
19. Bahnson P, Marsh W, Dial G. The associations among serology
to M. hyopneumoniae, lesions at slaughter, and a clinical
index of cough in groups of growing pigs. Proc IPVS. 1994:131.
36. Jacques M, Rioux S, Archambault M, Foiry B, Galameau C,
Luki N. Evaluation of the effects of tiamulin and valnemulin on
the growth and production of virulence factors of Actinobacillus
pleuropneumoniae and Pasteurella multocida. Proc
IPVS. 1998:270.
|
|